MedTrace Logo

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

NCT01999101 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-09-29

No results posted yet for this study

Summary

The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.

Conditions

  • Non Alcoholic Fatty Liver Disease

Interventions

DRUG

Px-104

28 days treatment

Sponsors & Collaborators

  • Medical University of Vienna

    collaborator OTHER

  • Phenex Pharmaceuticals AG

    lead INDUSTRY

Principal Investigators

  • Michael Trauner, Professor Dr med · Medical University Vienna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-01-31
Completion
2016-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01999101 on ClinicalTrials.gov